LivaNova PLC (LIVN)
NASDAQ: LIVN · IEX Real-Time Price · USD
52.91
-0.19 (-0.36%)
At close: Jul 19, 2024, 4:00 PM
52.82
-0.09 (-0.17%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
LivaNova Revenue
LivaNova had revenue of $1.19B in the twelve months ending March 31, 2024, with 13.40% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $294.91M with 11.96% year-over-year growth. In the year 2023, LivaNova had annual revenue of $1.15B with 12.89% growth.
Revenue (ttm)
$1.19B
Revenue Growth
+13.40%
P/S Ratio
2.42
Revenue / Employee
$408,634
Employees
2,900
Market Cap
2.87B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
Dec 31, 2022 | 1.02B | -13.56M | -1.31% |
Dec 31, 2021 | 1.04B | 101.12M | 10.82% |
Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
Dec 31, 2019 | 1.08B | -22.79M | -2.06% |
Dec 31, 2018 | 1.11B | 94.68M | 9.35% |
Dec 31, 2017 | 1.01B | 47.42M | 4.91% |
Dec 31, 2016 | 964.86M | 673.30M | 230.93% |
Apr 24, 2015 | 291.56M | 9.54M | 3.38% |
Apr 25, 2014 | 282.01M | 27.69M | 10.89% |
Apr 26, 2013 | 254.32M | -426.21M | -62.63% |
Dec 31, 2012 | 680.53M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
agilon health | 4.78B |
Envista Holdings | 2.56B |
ICU Medical | 2.26B |
ACADIA Pharmaceuticals | 813.81M |
Tandem Diabetes Care | 770.01M |
Azenta | 651.76M |
Denali Therapeutics | 295.39M |
MorphoSys AG | 264.75M |
LIVN News
- 1 day ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN - GlobeNewsWire
- 7 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN - Accesswire
- 27 days ago - Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach - Business Wire
- 4 weeks ago - LivaNova to Announce Second-Quarter 2024 Results - Business Wire
- 6 weeks ago - LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients - Business Wire
- 2 months ago - LivaNova to Present at the Goldman Sachs Healthcare Conference - Business Wire
- 2 months ago - LivaNova Reports First-Quarter 2024 Results - Business Wire
- 2 months ago - LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer - Business Wire